MYCN and neuroblastoma: Median-effect analysis was used to determine whether RG7388 can synergise with these chemotherapies in non-MYCN amplified SHSY5Y, MYCN amplified LAN5, and MDM2 and MYCN co-amplified NGP, LS and NB1691 p53 wt neuroblastoma cell lines.